DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT04865744

CompletedPhase 4

The Effect of Semaglutide on Pituitary Function

Asset

Semaglutide

Oral · GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

10

actual

Study population

Healthy volunteers

Key I/E criterion

—

Primary endpoint

•Growth hormone peak

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT04865744
Org study IDSema21

Timeline

Milestones

Study first posted2021-04-29actual
Study start2021-05-19actual
Primary completion2021-09-23actual
Study completion2021-09-30actual
Last update posted2023-02-22actual

Assets

Investigational agents

Semaglutide

Study populations

Who this study enrolls

Healthy volunteers

Eligibility

Who can enroll

Minimum age18 Years
Maximum age50 Years
SexAll
Healthy volunteersAccepted

Inclusion criteria

•Age 18-50 years
•The body weight >65 kg

Exclusion criteria

•presence of chronic illness
•the daily use of medications
•pregnancy
•lactation.

Endpoints (10)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other (unclassified)
5
Glycemic / diabetes
2
Cardiometabolic biomarkers
2
Safety / tolerability / PK
1

Glycemic / diabetes

2 endpoints
Secondary/protocol endpoint

Glucose nadir

Time frame:60, 90, 120, 150, 180 and 240 minutes after study medication administration

descriptive

Secondary/protocol endpoint

C-peptide peak

Time frame:60, 90, 120, 150, 180 and 240 minutes after study medication administration

concentration, descriptive

Cardiometabolic biomarkers

2 endpoints
Other/protocol endpoint

Heart rate

Time frame:60, 90, 120, 150, 180 and 240 minutes after study medication administration

Heart rate, change

change from baseline, improvement

Other/protocol endpoint

Blood pressure

Time frame:60, 90, 120, 150, 180 and 240 minutes after study medication administration

change from baseline, improvement

Safety / tolerability / PK

1 endpoint
Other/protocol endpoint

Nausea

Time frame:60, 90, 120, 150, 180 and 240 minutes after study medication administration

Nausea

descriptive

Other (unclassified)

5 endpoints
Primary/protocol endpoint/low confidence

Growth hormone peak

Time frame:60, 90, 120, 150, 180 and 240 minutes after study medication administration

concentration, descriptive

Secondary/protocol endpoint

Cortisol peak

Time frame:60, 90, 120, 150, 180 and 240 minutes after study medication administration

concentration, descriptive

Secondary/protocol endpoint/low confidence

Adrenocorticotropin (ACTH) peak

Time frame:60, 90, 120, 150, 180 and 240 minutes after study medication administration

concentration, descriptive

Secondary/protocol endpoint

Aldosterone peak

Time frame:60, 90, 120, 150, 180 and 240 minutes after study medication administration

concentration, descriptive

Secondary/protocol endpoint/low confidence

Copeptin peak

Time frame:60, 90, 120, 150, 180 and 240 minutes after study medication administration

concentration, descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.